Literature DB >> 15653958

Parasympathetic airway response and heart rate variability before and at the end of methacholine challenge.

Aurélien Pichon1, Claire de Bisschop, Véronique Diaz, André Denjean.   

Abstract

BACKGROUND: The autonomic nervous system plays a primary role in regulating airway caliber, and its dysfunction is likely to contribute to the pathogenesis of airways diseases. Moreover, some findings support the hypothesis that autonomic dysfunction and/or dysregulation contributes to the pathogenesis of airway hyperresponsiveness (AHR). Heart rate variability (HRV) spectral analysis allows identifying noninvasively perturbations of the autonomic system. PURPOSES: We tested the relationship between AHR and cardiac parasympathetic tone assessed by HRV spectral analysis in patients submitted to a diagnostic methacholine bronchial challenge (MBC).
METHODS: Fifteen women and 38 men (age range, 18 to 56 years) participated in the study. The principal indications for MBC were suspected asthma, chronic cough, unexplained exercise-induced dyspnea, or cough. The R-R intervals were continuously recorded during the MBC. Autoregressive method was performed on two series of 256 R-R intervals extracted before and after the MBC to obtain low-frequency (LF) and high-frequency (HF) components.
RESULTS: The MBC distinguished 29 subjects without airway responsiveness (R-) and 24 responder or hyperresponsive subjects (R+): mean provocative dose of methacholine causing a 20% reduction in mean (+/- SD) FEV1 of 467 +/- 351 microg (range, 70 to 1,426 microg). The HF component expressed in normalized units (n.u.) [the index of parasympathetic modulation] was significantly higher in R+ than in R- at baseline, before MBC (21 +/- 21 n.u. vs 11 +/- 9 n.u., p < 0.05). Interestingly, R+ showed a significant increase of HF component after MBC (243 +/- 30 to 567 +/- 620 ms2 and 21 +/- 21 to 34 +/- 30 n.u., p < 0.01). For all subjects, HF (n.u.) calculated at baseline and after MBC were significantly influenced by the bronchial responsiveness (r2 = -0.28 and -0.51, respectively; p < 0.001).
CONCLUSION: In summary, we found that R+ had a significantly higher parasympathetic tone than R- at baseline, and that R+ showed a significant increase in cardiac reactivity after bronchial challenge. These findings demonstrate that the autonomic nervous system, which contributes to the pathogenesis of AHR, is closely linked to cardiac modulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653958     DOI: 10.1378/chest.127.1.23

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Complexity analysis of heart rate variability in chronic obstructive pulmonary disease: relationship with severity and symptoms.

Authors:  Nelson Francisco Serrão; Alberto Porta; Vinicius Minatel; Antônio A M Castro; Aparecida Maria Catai; Luciana Maria Malosá Sampaio; Ross Arena; Audrey Borghi-Silva
Journal:  Clin Auton Res       Date:  2020-01-14       Impact factor: 4.435

2.  Airway response to methacholine following eucapnic voluntary hyperpnea in athletes.

Authors:  Valérie Bougault; Evelyne Blouin; Julie Turmel; Louis-Philippe Boulet
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

3.  School environment associates with lung function and autonomic nervous system activity in children: a cross-sectional study.

Authors:  Inês Paciência; João Cavaleiro Rufo; Diana Silva; Carla Martins; Francisca Mendes; Tiago Rama; Ana Rodolfo; Joana Madureira; Luís Delgado; Eduardo de Oliveira Fernandes; Patrícia Padrão; Pedro Moreira; Milton Severo; Maria Fátima Pina; João Paulo Teixeira; Henrique Barros; Lasse Ruokolainen; Tari Haahtela; André Moreira
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

4.  Dynamic Changes in Heart Rate Variability and Nasal Airflow Resistance during Nasal Allergen Provocation Test.

Authors:  Tiina M Seppänen; Olli-Pekka Alho; Tapio Seppänen
Journal:  J Healthc Eng       Date:  2016       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.